{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"306.2","upperLimit":"594.9","value":"426.8"},{"groupId":"OG001","lowerLimit":"586.1","upperLimit":"920.3","value":"734.4"},{"groupId":"OG002","lowerLimit":"1238","upperLimit":"1934","value":"1547"},{"groupId":"OG003","lowerLimit":"1664","upperLimit":"2692","value":"2116"},{"groupId":"OG004","lowerLimit":"110.9","upperLimit":"958.7","value":"326.1"},{"groupId":"OG005","lowerLimit":"1100","upperLimit":"1425","value":"1252"},{"groupId":"OG006","lowerLimit":"1404","upperLimit":"2260","value":"1781"},{"groupId":"OG007","lowerLimit":"1480","upperLimit":"2078","value":"1754"},{"groupId":"OG008","lowerLimit":"1361","upperLimit":"2146","value":"1709"},{"groupId":"OG009","lowerLimit":"871.5","upperLimit":"1371","value":"1093"}]}],"title":"Day 1 (n=6, 10, 25, 13, 4, 3, 25, 23, 18, 15)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"405.7","upperLimit":"963.9","value":"625.3"},{"groupId":"OG001","lowerLimit":"747.6","upperLimit":"1088","value":"902.0"},{"groupId":"OG002","lowerLimit":"1170","upperLimit":"2236","value":"1617"},{"groupId":"OG003","lowerLimit":"2185","upperLimit":"2980","value":"2552"},{"groupId":"OG004","lowerLimit":"201.0","upperLimit":"2974","value":"773.1"},{"comment":"Data was not estimable if evaluable subjects were less than 3 as per the planned decision because only 2 collected values were not sufficient to calculate a reliable estimation.","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG006","lowerLimit":"1713","upperLimit":"2663","value":"2136"},{"groupId":"OG007","lowerLimit":"1540","upperLimit":"2318","value":"1889"},{"groupId":"OG008","lowerLimit":"1487","upperLimit":"2658","value":"1988"},{"groupId":"OG009","lowerLimit":"1141","upperLimit":"1988","value":"1506"}]}],"title":"Day 15 (n=6, 9,15,9, 3, 1, 16, 17, 10, 13)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"26"},{"groupId":"OG007","value":"24"},{"groupId":"OG008","value":"18"},{"groupId":"OG009","value":"15"}],"units":"Participants"}],"description":"Area under the concentration-time curve from time 0 to the last quantifiable concentration.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 15 milligram (mg) on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE cohort).","id":"OG000","title":"Pimasertib (MSC1936369B) 15mg"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 30 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE cohort).","id":"OG001","title":"Pimasertib (MSC1936369B) 30mg"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE cohort).","id":"OG002","title":"Pimasertib (MSC1936369B) 60mg"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 90 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE cohort).","id":"OG003","title":"Pimasertib (MSC1936369B) 90mg"},{"description":"Pimasertib (MSC1936369B) capsule administered twice, orally, at a dose of 45 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE cohort).","id":"OG004","title":"Pimasertib (MSC1936369B) 45mg Twice Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered twice, orally, at a dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE cohort).","id":"OG005","title":"Pimasertib (MSC1936369B) 60mg Twice Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG006","title":"TNBC: Pimasertib 60mg Once Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG007","title":"NSCLC: Pimasertib 60mg Once Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG008","title":"CRC: Pimasertib 60mg Once Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG009","title":"MEL: Pimasertib 60mg Once Daily"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK analysis set . Here \"n\" signifies the number of subjects evaluable at the specific time points.","reportingStatus":"POSTED","timeFrame":"Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts","title":"Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to the Last Sampling Time (0-24 Hours) of Pimasertib (MSC1936369B)","type":"SECONDARY","unitOfMeasure":"hour*nanogram per millilitre (hr*ng/mL)"}